These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21401729)

  • 1. Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response.
    Weimer R; Deisz S; Dietrich H; Renner F; Bödeker RH; Daniel V; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
    Transpl Int; 2011 Jun; 24(6):596-609. PubMed ID: 21401729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil.
    Weimer R; Süsal C; Yildiz S; Streller S; Pelzl S; Staak A; Renner F; Dietrich H; Daniel V; Feuring E; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
    Transplant Proc; 2005 May; 37(4):1776-8. PubMed ID: 15919463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cytokine responses in liver transplant recipients treated with cyclosporine A and tacrolimus.
    Golling M; Sadeghi M; Zipperle S; Fonouni H; Golriz M; Mehrabi A
    Clin Transplant; 2009 Dec; 23 Suppl 21():83-91. PubMed ID: 19930321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses.
    Weimer R; Melk A; Daniel V; Friemann S; Padberg W; Opelz G
    Hum Immunol; 2000 Sep; 61(9):884-97. PubMed ID: 11053632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
    Pham PT; Pham PC
    Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols.
    Legris T; Picard C; Moal V; Burtey S; Loundou A; Purgus R; Dussol B; Berland Y; Vacher-Coponat H
    Ann Transplant; 2013 Nov; 18():622-34. PubMed ID: 24231646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
    Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
    J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
    Kimball JA; Pescovitz MD; Book BK; Norman DJ
    Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects.
    Renner FC; Dietrich H; Bulut N; Celik D; Freitag E; Gaertner N; Karoui S; Mark J; Raatz C; Weimer R; Feustel A
    Transplant Proc; 2013 May; 45(4):1608-10. PubMed ID: 23726630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
    Rentenaar RJ; van Diepen FN; Meijer RT; Surachno S; Wilmink JM; Schellekens PT; Pals ST; van Lier RA; ten Berge IJ
    Kidney Int; 2002 Jul; 62(1):319-28. PubMed ID: 12081594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine.
    Vacher-Coponat H; Brunet C; Moal V; Loundou A; Bonnet E; Lyonnet L; Ravet S; Sampol-Manos E; Sampol J; Berland Y; George FD; Paul P
    Transplantation; 2006 Aug; 82(4):558-66. PubMed ID: 16926601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up.
    Ducloux D; Motte G; Billerey C; Bresson-Vautrin C; Vautrin P; Rebibou JM; Saint-Hillier Y; Chalopin JM
    Transpl Int; 2002 Sep; 15(8):387-92. PubMed ID: 12221456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.